In skin lesions caused by pemphigus, a group of life-threatening autoimmune bullous diseases, an over-representation of CD4 tissue-resident memory T (T) cells was found. We sought to investigate the contributions of CD4 T cells to the severity and refractoriness of pemphigus and their role in local immunological pathogenesis. Our data showed that CD4 T cells accumulated significantly in pemphigus skin lesions. These CD4 T cells expressed a specific set of T follicular helper cell‒related costimulatory molecules. We also found that CD4 T cells remaining in the lesions produced IL-17A and IL-21. In vitro, CD4 T cells exhibited strong support and assistance to autoantibody production. Through transcriptomic sequencing and bioinformatics analysis, we identified that the transcription factor IRF4 was responsible for IL-21 overexpression and autoantibody production. Our results showed that T follicular helper-like CD4 T cells in pemphigus lesions promoted local autoantibody production, resulting in the formation and recurrence of lesions, which supports targeting this cell subset in pemphigus treatment. IRF4 might serve as a potential therapeutic target.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2021.01.030DOI Listing

Publication Analysis

Top Keywords

cd4 cells
24
autoantibody production
12
cd4
8
cd4 tissue-resident
8
tissue-resident memory
8
cells
8
memory cells
8
follicular helper-like
8
pemphigus lesions
8
skin lesions
8

Similar Publications

Agonistic anti-CD40 with anti-PD-1 can elicit objective responses in a small number of patients with pancreatic ductal adenocarcinoma (PDA). Better understanding of their individual effects on the PDA tumor microenvironment will help inform new strategies to further improve outcomes. Herein, we map tumor-specific CD8+ T-cell differentiation following agonistic anti-CD40 and/or anti-PDL1 in PDA.

View Article and Find Full Text PDF

HGF-DPSCs ameliorate asthma by regulating CCR1 Th2 cells responses in mice pulmonary mucosa.

Cytotherapy

February 2025

Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China. Electronic address:

Asthma, a prevalent allergic disease affecting approximately 300 million individuals globally, remains a significant public health challenge. Mesenchymal stromal cells (MSCs) and hepatocyte growth factor (HGF), both recognized for their immunomodulatory properties, hold therapeutic potential for asthma. However, their precise mechanisms remain underexplored.

View Article and Find Full Text PDF

A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.

View Article and Find Full Text PDF

The progression of COVID-19 involves a sophisticated and intricate interplay between the SARS-CoV-2 virus and the host's immune response. The immune system employs both innate and adaptive mechanisms to combat infection. Innate immunity initiates the release of interferons (IFNs) and pro-inflammatory cytokines, while the adaptive immune response involves CD4+ Th lymphocytes, B lymphocytes, and CD8+ Tc cells.

View Article and Find Full Text PDF

Human immunodeficiency virus (HIV) infection continues to be a major global health challenge, affecting 38.4 million according to the Joint United Nations Program on HIV/AIDS (UNAIDS) at the end of 2021 with 1.5 million new infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!